Active Biotech AB Interim Report January - September 2013

LUND, Sweden, Nov. 7, 2013 (GLOBE NEWSWIRE) --

Laquinimod * Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage; Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration * New data presented at ECTRIMS shows that laquinimod has an effect on both inflammation and the underlying mechanisms associated with disease progression in multiple sclerosis * Teva is planning to commence clinical trials in Huntington's disease and primary progressive multiple sclerosis (PPMS) * Teva will initiate a further clinical trial in multiple sclerosis (LIBRETTO) Tasquinimod * Phase III 10TASQ10 study is proceeding as planned; the primary analysis of progression-free survival (PFS) and survival (OS) is expected in 2014 * Active Biotech received a milestone payment of EUR 12 M from Ipsen ANYARA * Detailed analysis provides further support for ANYARA's efficacy in a biomarker-defined sub-group of renal cell cancer patients; the result from the Phase II/III study was presented at the 2013 European Cancer Congress Paquinimod (57-57) * Evaluation under way of clinical trial in systemic sclerosis ISI * Project proceeding according to plan Financial summary SEK M Q3 Jan Jan - Sept - Dec 2013 2012 2013 2012 2012 ------------------------------------------------------------------------------- Net sales 107.0 39.8 111.9 136.4 227.9 Operating loss 27.9 -48.2 -128.6 -168.7 -163.2 Profit/Loss 29.2 -51.6 -130.0 -175.1 -175.0 after tax Profit/loss per 0.39 -0.75 -1.77 -2.54 -2.54 share For further information, please contact: Tomas Leanderson, President and CEO Tel: +46 (0)46-19 20 95 Hans Kolam, CFO Tel: +46 (0)46-19 20 44 Active Biotech AB(Corp. Reg. No. 556223-9227) Box 724, 220 07 Lund Tel: +46 (0)46-19 20 00 Fax +46 (0)46-19 11 00 The report is also available at www.activebiotech.com Active Biotech AB Interim Report January – September 2013 : http://hugin.info/1002/R/1741192/584931.pdf [HUG#1741192] Source:Active Biotech